Vext Announces Change of Auditor
Vext Announces Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - March 8, 2024) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company"), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, today announced it has changed its auditor from BF Borgers CPA PC (the "Former Auditor") to Reliant CPA (the "Successor Auditor") effective March 8, 2024. The Company changed its auditor from the Former Auditor to the Successor Auditor for the reasons that follow.
不列顛哥倫比亞省溫哥華--(Newsfile Corp.-2024 年 3 月 8 日)- Vext Science, Inc (案例:VEXT)(OTCAX:VEXTF)(”Vext“或者”公司“)是一家總部位於美國的大麻運營商,在亞利桑那州和俄亥俄州開展垂直業務,今天宣佈其核數師已從BF Borgers CPA PC(”前審計員“) 到 Reliant CPA(”繼任核數師“) 於 2024 年 3 月 8 日生效。出於以下原因,該公司將其核數師從前核數師改爲繼任核數師。
Background
背景
On December 7, 2023, the Canadian Public Accountability Board ("CPAB") issued an enforcement report (the "Enforcement Report") against the Former Auditor resulting from an engagement findings report dated October 12, 2023 (the "CPAB Report") with respect to work completed by the Former Auditor on the Company's audited financial statements for the year ended December 31, 2022 (the "2022 Statements").
2023 年 12 月 7 日,加拿大公共問責委員會(”CPAB“)發佈了執法報告(”執法報告“) 根據2023年10月12日的參與調查結果報告對前核數師提起訴訟(”CPAB 報告“) 關於前核數師完成的公司截至2022年12月31日止年度的經審計財務報表的工作(”2022年聲明“)。
The Enforcement Report identified multiple significant inspection findings, each of which constitute a separate Violation Event (as defined in the Rules of CPAB) with respect to the Former Auditor. A summary of the findings in the CPAB Report is set forth in the change of auditor notice that was filed today and is available on SEDAR+.
執法報告確定了多項重要的檢查結果,每項調查結果都構成了針對前核數師的單獨違規事件(定義見CPAB規則)。CPAB報告中的調查結果摘要載於今天提交的核數師變更通知,可在SEDAR+上查閱。
In addition, among the various enforcement actions, the Former Auditor is prohibited from accepting Canadian reporting issuers as clients and is prohibited from assigning a certain unnamed partner to audits of financial statements of reporting issuers in any Canadian jurisdiction in which the unnamed partner is not properly licensed to provide public accounting services by the relevant provincial Chartered Professional Accountant regulatory body, which was a factor in the Former Auditor's resignation. A copy of the Enforcement Report is available here.
此外,在各種執法行動中,禁止前核數師接受加拿大申報發行人作爲客戶,也禁止指派某個不願透露姓名的合夥人對任何加拿大司法管轄區的申報發行人的財務報表進行審計,因爲相關省級特許專業會計師監管機構沒有向該未透露姓名的合夥人提供公共會計服務的適當許可,這是前核數師辭職的一個因素。執法報告的副本可在此處獲得。
Resignation
辭職
The Former Auditor resigned as the auditor of the Company on its own initiative effective March 8, 2024 and the board of directors of the Company (the "Board") appointed the Successor Auditor as the Company's auditor effective March 8, 2024, until the next annual general meeting of shareholders of the Company.
前核數師自2024年3月8日起主動辭去公司核數師職務,並辭去公司董事會(”板“)任命繼任核數師爲公司核數師,自2024年3月8日起生效,直至公司下一次年度股東大會。
The Company confirms that, at this time, there have been no reservations or modified opinions in the Former Auditor's reports for any period during which the Former Auditor was the auditor of the Company. The Board has approved the resignation of the Former Auditor and the appointment of the Successor Auditor in place of the Former Auditor.
公司證實,目前,在前核數師擔任公司核數師的任何時期,前核數師的報告中均未提出任何保留意見或修改意見。董事會已批准前核數師的辭職和任命繼任核數師取代前審計員。
CPAB Report Findings
CPAB 報告調查結果
The Former Auditor was required to provide a written response to CPAB and has advised the Company that it has provided such response. As of the date hereof, the Company is not aware of any requirement to restate the 2022 Statements. The Company intends to promptly respond to any information requests by the Former Auditor with respect to any applicable remediation plan.
前核數師被要求向CPAB提供書面答覆,並已告知該公司已提供了此類答覆。截至本文發佈之日,公司尚無任何重述2022年聲明的要求。公司打算立即回應前核數師就任何適用的補救計劃提出的任何信息請求。
The fact of the CPAB Report, including its underlying findings, the Enforcement Report and the outstanding remediation actions, if any, is an "unresolved issue" constituting a "reportable event" pursuant to National Instrument 51-102 Continuous Disclosure Obligations ("NI 51-102") as it could have a material impact on the auditor report provided on the 2022 Statements. The audit committee of the Board (the "Audit Committee") has discussed the CPAB Report with the Former Auditor and authorizes the Former Auditor to respond fully to inquiries by the Successor Auditor concerning the CPAB Report and Enforcement Report. The Successor Auditor has provided an oral "consultation" (as such term is defined in NI 51-102), which is a "reportable event" (as such term is defined in NI 51-102), with respect to the CPAB Report and the impact on the scope of the audit for the Company's fiscal year ended December 31, 2023. Pursuant to such consultation, the Successor Auditor has advised that it agrees with the Company's determination of the impact on assurances placed on the 2022 Statements as set out in Appendix A to the change of auditor notice; however, the Successor Auditor expects to perform additional procedures on year-end 2022 balances and transactions and/or modify its independent auditor's report to the extent that may be necessary. Other than as set out elsewhere herein, neither the Successor Auditor nor the Company has consulted with the Former Auditor with respect to such matters.
根據國家儀器51-102,CPAB報告的事實,包括其基本調查結果、執法報告和懸而未決的補救行動(如果有)是 “未解決的問題”,構成 “應報告的事件” 持續披露義務 (”在 51-102“)因爲它可能會對2022年報表中提供的審計報告產生重大影響。董事會的審計委員會(”審計委員會“)已與前核數師討論了CPAB報告,並授權前核數師全面回應繼任核數師對CPAB報告和執法報告的詢問。繼任核數師就CPAB報告及其對截至2023年12月31日的公司財年審計範圍的影響進行了口頭 “諮詢”(該術語的定義見NI 51-102),這是 “應報告的事件”(該術語的定義見NI 51-102)。根據此類磋商,繼任核數師表示,它同意公司在核數師變更通知附錄A中對2022年報表所作保證的影響的決定;但是,繼任核數師預計將在必要的情況下對2022年年底的餘額和交易執行額外程序和/或修改其獨立核數師的報告。除本文其他地方所述外,繼任核數師和公司均未就此類事項與前核數師進行過磋商。
The Company will continue to update the market with respect to the foregoing.
公司將繼續就上述內容向市場通報最新情況。
Change of Auditor Notice
核數師變更通知
In accordance with NI 51-102, the change of auditor notice, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed and approved, as applicable, by the Board and have been filed on SEDAR+.
根據NI 51-102,審計員變更通知以及前核數師和繼任核數師所需的信函已由董事會酌情審查和批准,並已在SEDAR+上提交。
About Vext Science, Inc.
關於 Vext Science, Inc.
Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio. Vext's expertise spans from cultivation through to retail operations in its key markets. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio, as well as through Vext's partnerships in other states. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations, with the Company having operated profitably since 2016. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value.
Vext Science, Inc. 是一家總部位於美國的大麻運營商,在亞利桑那州和俄亥俄州開展垂直業務。Vext的專業知識涵蓋了從種植到關鍵市場的零售業務。Vext總部位於亞利桑那州,在亞利桑那州和俄亥俄州擁有並經營最先進的種植設施、完全建成的製造設施以及藥房。該公司生產Vapen,這是亞利桑那州領先的四氫大麻酚濃縮物、零食和餾出液瓶裝品牌之一。其精選的獲獎產品採用Vext的自產優質花卉製成,銷往亞利桑那州和俄亥俄州,並通過Vext在其他州的合作伙伴關係進行分銷。Vext的領導團隊在建立和運營盈利的多州業務方面有着良好的記錄,該公司自2016年以來一直實現盈利。公司的主要重點是繼續在其核心州亞利桑那州和俄亥俄州發展,將尖端科學、製造和營銷相結合,提供可靠和有價值的客戶體驗,同時創造股東價值。
Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at and connect with Vext on Twitter/X and LinkedIn.
Vext Science, Inc. 在加拿大證券交易所上市,股票代碼爲VEXT,在OTCQX市場上交易,代碼爲VEXTF。要了解更多信息,請訪問 Twitter/X 和 LinkedIn 上的 Vext 並與其聯繫。
For more details on the Vapen brand:
Vapen website: VapenBrands.com
Instagram: @vapen
Facebook: @vapenbrands
有關 Vapen 品牌的更多詳情:
Vapen 網站:VapenBrands.com
Instagram:@vapen
Facebook:@vapenbrands
Forward Looking Statements
前瞻性陳述
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.
本新聞稿中的前瞻性陳述受與Vext向加拿大證券監管機構提交的定期文件中披露的特定因素有關的各種風險和不確定性的影響。在本新聞稿中使用諸如 “將、可能、計劃、估計、預期、打算、可能、潛力、相信、應該” 等詞語以及類似的表述方式均爲前瞻性陳述。
Forward-looking statements may include, without limitation, statements related to the appointment of auditors of the Company, any remediation steps with respect to the CPAB Report or the 2022 Statements, the Successor Auditor's audit of the Company's financial statements for the year ended December 31, 2023, and other statements regarding future developments, growth, and the business and operations of the Vext, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at .
前瞻性陳述可能包括但不限於與公司核數師的任命、與CPAB報告或2022年報表有關的任何補救措施、繼任核數師對截至2023年12月31日的公司財務報表的審計以及與Vext未來發展、增長以及業務和運營相關的其他陳述,所有這些都受Vext在SEDAR+上提交的持續披露中包含的風險因素的約束在。
Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.
儘管Vext試圖確定可能導致實際業績、業績或成就與前瞻性陳述中包含的結果存在重大差異的重要因素,但可能還有其他因素導致業績、業績或成就與預期、估計或預期不符,包括但不限於:依賴監管部門的批准;從事目前根據美國聯邦法律被視爲非法的活動;法律的變化;對管理的依賴;對額外融資的要求;競爭;由於公衆對醫療用途和成人用大麻行業的看法不一致,以及監管或政治變革,阻礙了市場增長和各州的採用。
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
無法保證此類信息會被證明是準確的,也無法保證管理層對未來發展、情況或結果的預期或估計會成爲現實。由於這些風險和不確定性,這些前瞻性陳述中預測的結果或事件可能與實際結果或事件存在重大差異。
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.
因此,讀者不應過分依賴前瞻性陳述。本新聞稿中的前瞻性陳述截至本新聞稿發佈之日作出。除非適用法律要求,否則Vext不打算或承擔任何更新或修改此類信息的意圖或義務,並且Vext對與本文提及的任何其他公司有關的披露不承擔任何責任。
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
加拿大證券交易所尚未審查、批准或不批准本新聞稿的內容。
Eric Offenberger
Chief Executive Officer
844-211-3725
埃裏克·奧芬伯格
首席執行官
844-211-3725
For further information:
Jonathan Ross, Vext Investor Relations
jon.ross@loderockadvisors.com
416-244-9851
欲了解更多信息:
喬納森·羅斯,Vext 投資者關係
jon.ross@loderockadvisors.com
416-244-9851
SOURCE: Vext Science, Inc.
來源:Vext Science, Inc.